Table 3.
CKD | Renal outcome | p | Death | p | eGFR slope difference | p | eGFR slope(active) | eGFR slope(inactive) | |
---|---|---|---|---|---|---|---|---|---|
Stage | HR (95% CI) | HR (95% CI) | ml/min/1.73m2, vs. inactive |
ml/min/1.73m2 | ml/min/1.73m2 | ||||
All | total | 1.00 (0.87, 1.16) | 0.96 | 0.62 (0.48, 0.82) | < 0.001 | 0.01 (-0.12, 0.15) | 0.83 | -1.56 (-1.63, 0.15) | -1.58 (-1.70, -1.45) |
G3b | 0.68 (0.44, 1.04) | 0.08 | 0.79 (0.40, 1.57) | 0.51 | 0.58 (0.21, 0.94) | 0.003 | -1.41 (-1.58, -1.24) | -1.98 (-2.28, -1.69) | |
G4 | 1.09 (0.86, 1.38) | 0.47 | 0.55 (0.38, 0.80) | 0.002 | -0.24(-0.45, -0.03) | 0.02 | -1.86 (-1.98, -1.75) | -1.62 (-1.79, -1.45) | |
G5 | 1.01 (0.82, 1.25) | 0.92 | 0.75 (0.44, 1.26) | 0.28 | -0.06(-0.18, 0.06) | 0.30 | -0.97 (-1.21, -0.72) | -0.87 (-1.16, -0.58) | |
Diabetic | total | 0.88 (0.66, 1.17) | 0.37 | 0.84 (0.52, 1.38) | 0.5 | 0.02 (-0.36, 0.40) | 0.91 | -1.72 (-1.92, -1.52) | -1.75 (-2.08, -1.41) |
G3b | 0.37 (0.15, 0.91) | 0.03 | 1.57 (0.27, 9.23) | 0.62 | 0.68 (-0.47, 1.83) | 0.24 | -1.80 (-2.34, -1.27) | -2.48 (-3.50, -1.47) | |
G4 | 0.89 (0.53, 1.49) | 0.65 | 1.04 (0.51, 2.15) | 0.91 | -0.26(-0.70, 0.17) | 0.23 | -1.85 (-2.09, -1.60) | -1.58 (-1.97, -1.20) | |
G5 | 0.93 (0.62, 1.40) | 0.74 | 0.78 (0.29, 2.05) | 0.61 | -0.10(-0.44, 0.24) | 0.56 | -0.97 (-1.21, -0.72) | -0.87 (-1.16, -0.58) | |
Non-diabetic | total | 1.05 (0.88, 1.25) | 0.58 | 0.60 (0.43, 0.83) | 0.002 | 0.01 (-0.16, 0.17) | 0.94 | -1.52 (-1.60, -1.44) | -1.53 (-1.67, -1.38) |
G3b | 0.73 (0.43, 1.23) | 0.23 | 0.66 (0.29, 1.49) | 0.32 | 0.42 (0.07, 0.76) | 0.02 | -1.36 (-1.53, -1.20) | -1.78 (-2.08, -1.47) | |
G4 | 1.10 (0.84, 1.44) | 0.49 | 0.39 (0.24, 0.62) | < 0.001 | -0.17 (-0.38, 0.04) | 0.12 | -1.81 (-1.94, -1.68) | -1.64 (-1.83, -1.45) | |
G5 | 1.05 80.81, 1.36) | 0.72 | 0.72 (0.37, 1.41) | 0.34 | -0.03 (-0.26, 0.21) | 0.82 | -1.08 (-1.20, -0.96) | -1.05 (-1.28, -0.83) |
HR hazard ratio, CI confidence interval, DKD diabetic kidney disease, CKD chronic kidney disease, p p-value, eGFR estimated glomerular filtration rate. Renal outcome was defined as a 40% decline in eGFR from baseline, an eGFR of less than 10 ml/min/1.73m2, or end-stage kidney disease requiring dialysis or transplantation, whichever occurred first.
The adjusted model includes adjustment for age, sex, smoking status, body mass index, eGFR, level of proteinuria, serum albumin, hemoglobin, diabetes, comorbidity score, cognitive heart failure, and lung disease.
Significant values are given in italics.